Skip to content
Weight Loss Pill Order TodayCheck It Out

How long does Mounjaro stay in your system?

Key takeaways

  • Tirzepatide's half-life is about five days, which is what makes once-weekly dosing work.
  • After a final dose, the medicine takes roughly four to five weeks to clear the body.
  • A missed dose can usually be taken within four days; beyond that, skip and resume schedule.
  • Side effects fade over days to weeks after stopping, tracking the falling drug level.
  • The long tail matters for pregnancy planning and for switching treatments; both are prescriber conversations.

How long Mounjaro stays in your system sounds like a single question, but people ask it for at least four different reasons: a missed dose, lingering side effects, a decision to stop, or a plan to become pregnant. The underlying number is the same in every case. Tirzepatide, the active medicine in Mounjaro, has an elimination half-life of around five days, among the longest of any weight-loss medicine, and everything practical about starting, missing, stopping and switching follows from that one figure. This article works through each situation.

The five-day half-life, explained simply

A half-life is the time the body takes to remove half of a medicine from the blood. Tirzepatide is built to bind to albumin, a blood protein, which shields it from rapid breakdown and stretches its half-life to roughly five days, or about 120 hours. That is the entire engineering behind once-weekly injection: by the time the next dose arrives, a substantial amount of the previous one is still working, so levels stay smooth rather than spiking and crashing. It also means the medicine accumulates when you start: each weekly dose adds to what remains of previous ones, with levels reaching a steady plateau after about four weeks at any given dose. That accumulation is one reason effects and side effects often build over the first month rather than arriving fully formed on day one.

How long after the last dose until it is gone?

The standard pharmacology rule of thumb is that a medicine is effectively cleared after four to five half-lives. For tirzepatide that means roughly 20 to 25 days, so around a month covers it comfortably: a week after your final injection, about half the steady-state level remains; after two weeks, a quarter; after three, an eighth; and by weeks four to five the amount left is clinically negligible. Individual clearance varies modestly with kidney function, body size and dose reached, but not enough to change the practical answer. If you need a single figure for planning purposes, one month after the last injection is the sensible working estimate for the medicine being out of your system.

What the long tail means when you stop

The slow exit has a gentle upside: stopping Mounjaro is not a cliff edge. Appetite suppression fades gradually over two to four weeks as levels fall, which gives you a window to consolidate eating habits while the medicine loosens its grip rather than losing all support overnight. The same applies to side effects: if nausea or reflux has been troubling you, expect improvement across days to a few weeks after stopping, not hours. The important caveat is what does not leave with the drug: the biology of appetite that made weight management difficult in the first place returns to its baseline, and trial evidence shows weight tends to regain over the following year without a maintenance plan. Stopping deserves as much structure as starting, ideally agreed with your prescriber, and our article on stopping GLP-1 treatment covers that ground fully.

Pregnancy planning: where the number really matters

The clearance timeline stops being trivia and becomes clinically important around pregnancy. Tirzepatide is not recommended during pregnancy or while trying to conceive, and because the medicine lingers for weeks after the last dose, guidance is to stop it at least one month before a planned pregnancy so it has genuinely cleared. There is a second, less obvious interaction: in women using oral contraception, tirzepatide's slowing of stomach emptying may reduce the pill's absorption, particularly around starting and dose increases, and additional barrier contraception is advised for four weeks after starting and after each dose escalation. Anyone who becomes pregnant while taking Mounjaro should stop and speak to their clinician promptly, without panic: the point of the guidance is precaution, and the right next step is a conversation rather than alarm.

Switching treatments and surgical pauses

Two more situations run on the same clock. Switching between weight-loss medicines, for example from tirzepatide to a semaglutide product or the reverse, is a prescriber-managed handover precisely because the outgoing medicine is still active for weeks; timing the first dose of the new treatment accounts for that overlap, and improvising the switch yourself risks stacking two active medicines or opening an unintended gap. And before planned surgery under anaesthesia, teams increasingly ask about GLP-1 medicines because slowed stomach emptying affects fasting plans and aspiration risk; tell your surgical, endoscopy or dental sedation team that you take Mounjaro and when your last dose was, and follow their instruction on whether and when to pause. In both cases the five-day half-life is the reason the professionals want the details, and the practical rule for you is simply to volunteer the information early rather than assuming a weekly injection is not worth mentioning.

The summary: Mounjaro works on a five-day half-life, reaches steady levels after about a month on a dose, and takes about a month to leave after the last injection. Miss a dose by under four days and take it; by more, skip it. Stop, and both benefits and side effects fade over weeks rather than days. Planning a pregnancy means a deliberate one-month clearance gap, agreed with your clinician. None of these decisions should be improvised alone, but all of them make more sense once you know the one number underneath. For the rest of the picture, see our guides to how Mounjaro works and its side effects.

Bottom line

  • Five-day half-life; effectively cleared four to five weeks after the final dose.
  • Missed dose: take within four days, otherwise skip; never double up.
  • Benefits and side effects both fade over weeks after stopping, and weight regain risk needs a plan.
  • Stop at least a month before a planned pregnancy; tell surgical teams about recent doses.

Frequently asked questions

How long does one dose of Mounjaro last?

Each weekly injection maintains active levels for well over a week, which is why dosing is weekly. After any single dose, about half remains at five days and traces persist for several weeks.

How long until Mounjaro side effects wear off after stopping?

Side effects generally ease across days to a few weeks after the final dose, tracking the falling drug level. Anything severe or worsening after stopping deserves clinical review rather than waiting.

How long should I stop Mounjaro before trying for a baby?

Guidance is to stop at least one month before a planned pregnancy so the medicine has cleared. Discuss timing and contraception with your clinician; oral contraception may also need barrier back-up after starting and dose increases.

Does Mounjaro show up in blood tests?

Routine NHS blood panels do not test for tirzepatide. It can be measured with specialised assays, but there is no standard test, and no practical reason for one outside research.

References

  1. electronic medicines compendium. Mounjaro KwikPen Summary of Product Characteristics. medicines.org.uk
  2. PubMed. Tirzepatide: clinical pharmacokinetics and pharmacodynamics. pubmed.ncbi.nlm.nih.gov
  3. NHS. Tirzepatide. nhs.uk

Why trust our experts?

Every Health Hub article goes through rigorous fact-checking by our team of medical reviewers. Our reviewers are trained medical professionals who ensure each article contains up-to-date information and that medical details have been correctly interpreted.

  • Curate Clinical Team, GPhC

    UK-registered prescribing pharmacists who review Health Hub articles for clinical accuracy.